{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-028807","form_type":"8-K","ticker":"HCWB","cik":"0001828673","company_name":"HCW Biologics Inc.","filed_at":"2026-06-16T11:15:40+00:00","discovered_at":"2026-06-16T11:20:00.296163+00:00","generated_at":"2026-06-16T11:20:34.846863+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"HCW Biologics Reports Positive Preliminary Human Data for HCW9302 Phase 1 Trial in Alopecia Areata","bullets":["All three patients in second dose cohort (3 µg/kg) showed ≥25% reduction in SALT scores after single dose, indicating clinical response.","No dose-limiting toxicities, capillary leak, cytokine release syndrome, or increased eosinophil counts reported; only mild injection-site reactions.","Company projects to establish Recommended Phase 2 Dose by year-end 2026 and is dosing third cohort (8 µg/kg).","HCW9302 is a first-in-kind IL-2 based fusion immunotherapeutic with strong IL-2Rα bias, potentially best-in-class for autoimmune diseases.","CEO Hing C. Wong stated results consistent with preclinical studies showing Treg expansion and reduced inflammation."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-028807","json":"https://secwatch.observer/filing/0001493152-26-028807.json","markdown":"https://secwatch.observer/filing/0001493152-26-028807.md","text":"https://secwatch.observer/filing/0001493152-26-028807.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/0001493152-26-028807-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828673/000149315226028807/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T11:20:34.846863+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}